NYSEAMERICAN:ZOM - Zomedica Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.30
  • Forecasted Upside: -43.40 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.53
▲ +0.01 (1.92%)

This chart shows the closing price for ZOM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Zomedica Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZOM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZOM

Analyst Price Target is $0.30
▼ -43.40% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Zomedica in the last 3 months. The average price target is $0.30, with a high forecast of $0.30 and a low forecast of $0.30. The average price target represents a -43.40% upside from the last price of $0.53.

This chart shows the closing price for ZOM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Zomedica. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/28/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/27/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/25/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/24/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/16/2020HC WainwrightLower Price TargetBuy$0.50 ➝ $0.30
8/12/2020HC WainwrightReiterated RatingBuy$0.50
6/17/2020HC WainwrightReiterated RatingBuy$0.65 ➝ $0.50
6/5/2019HC WainwrightReiterated RatingBuy
(Data available from 9/24/2016 forward)

News Sentiment Rating

0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 23 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
2/26/2021
  • 0 very positive mentions
  • 20 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/28/2021
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/27/2021
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/27/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/26/2021
  • 0 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/26/2021
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/25/2021
  • 1 very positive mentions
  • 21 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
9/24/2021

Current Sentiment

  • 1 very positive mentions
  • 21 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Zomedica logo
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA, a diagnostic biosensor platform for the detection of thyroid disorders in dogs and cats, and adrenal disorders in dogs. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
Read More

Today's Range

Now: $0.53
Low: $0.52
High: $0.54

50 Day Range

MA: N/A

52 Week Range

Now: $0.53
Low: $0.06
High: $2.91

Volume

12,788,863 shs

Average Volume

84,620,188 shs

Market Capitalization

$519.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.41

Frequently Asked Questions

What sell-side analysts currently cover shares of Zomedica?

The following Wall Street research analysts have issued stock ratings on Zomedica in the last twelve months: HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for ZOM.

What is the current price target for Zomedica?

1 Wall Street analysts have set twelve-month price targets for Zomedica in the last year. Their average twelve-month price target is $0.30, suggesting a possible downside of 43.4%. HC Wainwright has the highest price target set, predicting ZOM will reach $0.30 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $0.30 for Zomedica in the next year.
View the latest price targets for ZOM.

What is the current consensus analyst rating for Zomedica?

Zomedica currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ZOM will outperform the market and that investors should add to their positions of Zomedica.
View the latest ratings for ZOM.

How do I contact Zomedica's investor relations team?

Zomedica's physical mailing address is 100 PHOENIX DRIVE SUITE 125, ANN ARBOR MI, 48108. The company's listed phone number is 734-369-2555 and its investor relations email address is [email protected] The official website for Zomedica is www.zomedica.com.